Evidence map›Paper›PMID 31320816›Full record

ArticleTurkish journal of biology = Turk biyoloji dergisi2019

Squalene attenuates the oxidative stress and activates AKT/mTOR pathway against cisplatin-induced kidney damage in mice.

Arzu Sakul, Mehmet Ozansoy, Birsen Elibol, Şule Ayla, Mehmet Yalçın Günal, Yasemin Yozgat, Hüveyda Başağa, Kazım Şahin, Rümeyza Kazancioğlu, Ülkan Kiliç

Open access · diamondAbstract read
In one paragraph

Article in Turkish journal of biology = Turk biyoloji dergisi, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Nontargeted metabonomics analysis ofFrontiers in microbiology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Arzu SakulDepartment of Medical Pharmacology, School of Medicine, İstanbul Medipol University, İstanbul, Turkey.ORCID https://orcid.org/0000-0002-9354-0000
Mehmet OzansoyDepartment of Physiology, School of Medicine, İstanbul Medipol University, İstanbul, Turkey.ORCID https://orcid.org/0000-0002-1079-8832
Birsen ElibolDepartment of Medical Biology, Faculty of Medicine, Bezmialem Vakıf University, İstanbul, Turkey.ORCID https://orcid.org/0000-0002-9462-0862
Şule AylaDepartment of Histology and Embryology, School of Medicine, İstanbul Medipol University, İstanbul, Turkey.ORCID https://orcid.org/0000-0003-2143-5268
Mehmet Yalçın GünalDepartment of Physiology, Alanya Alaaddin Keykubat University School of Medicine, Antalya, Turkey.ORCID https://orcid.org/0000-0001-7702-2441
Yasemin YozgatRegenerative and Restorative Medical Research Center (REMER), İstanbul Medipol University, İstanbul, Turkey.ORCID https://orcid.org/0000-0003-1580-8371
Hüveyda BaşağaBiological Sciences and Bioengineering Program, Faculty of Engineering and Natural Sciences, Sabancı University, İstanbul, Turkey.ORCID https://orcid.org/0000-0001-8081-1222
Kazım ŞahinDepartment of Animal Nutrition, Faculty of Veterinary Medicine, Fırat University, Elazığ, Turkey.ORCID https://orcid.org/0000-0001-9542-5244
Rümeyza KazancioğluDepartment of Nephrology, Faculty of Medicine, Bezmialem Vakıf University, İstanbul, Turkey.ORCID https://orcid.org/0000-0003-1217-588X
Ülkan KiliçDepartment of Nephrology, Faculty of Medicine, Bezmialem Vakıf University, İstanbul, Turkey.ORCID https://orcid.org/0000-0002-6895-8560
Istanbul Medipol University · TRBezmiâlem Vakıf Üniversitesi · TRAlanya University · TRFırat University · TRSabancı Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical use of cisplatin, which is a first-line anticancer agent, is highly restricted due to its adverse effects on kidneys that lead to nephrotoxicity. Therefore, some potential reno-protective substances have been used in combination with cisplatin to cope with nephrotoxicity. Due to its high antitumor activity and oxygen-carrying capacity, we investigated the molecular effects of squalene against cisplatin-induced oxidative stress and kidney damage in mice. Single dose of cisplatin (7 mg/kg) was given to male Balb/c mice. Squalene (100 mg/kg/day) was administered orogastrically to mice for 10 days. Following sacrification, molecular alterations were investigated as analysis of the levels of oxidative stress index (OSI), inflammatory cytokines and cell survival-related proteins in addition to histopathological examinations in mice kidney tissue. The level OSI and Interferon-gamma (IFN-γ) decreased in the cisplatin and squalene cotreated mice compared to cisplatin-treated mice. Squalene treatment also increased the activation of protein kinase B (AKT). Furthermore, cisplatin-induced inactivation of mammalian target of rapamycin (mTOR) and histopathological damages were reversed by squalene. It may be suggested that squalene ameliorated the cisplatin-induced histopathological damages in the kidney through activation of AKT/mTOR signaling pathway by regulating the balance of the redox system due to its antioxidative effect.

Indexed as

AKTcisplatin-induced nephrotoxicitymicemTORoxidative-stresssqualene

Identifiers

PMID31320816
PMCPMC6620038
OpenAlexW2950458958

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.